Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Pfizer's Xalkori (crizotinib) to treat patients with ROS1-positive non-small cell lung cancer (NSCLC).
Subscribe to our email newsletter
ROS1-positive NSCLC occurs in approximately 1% of NSCLC cases and it represents a particular molecular subgroup of NSCLC.
The breakthrough therapy designation was based on a data from an expansion cohort of a global Phase I trial (Study 1001), which evaluated Xalkori in 50 patients with ROS1-positive advanced NSCLC.
Results from this trial showed that Xalkori exhibited marked anti-tumor activity in patients with ROS1-positive advanced NSCLC.
Pfizer Oncology Clinical Development and Medical Affairs senior vice-president and chief medical officer Dr Mace Rothenberg said: "We are excited that the FDA has granted Breakthrough Therapy designation for Xalkori as a potential treatment for patients with ROS1-positive NSCLC.
"Xalkori pioneered precision medicine for ALK-positive metastatic NSCLC, and ROS1 represents a second molecular subgroup of NSCLC in which Xalkori has demonstrated a level of anti-tumor activity that can potentially make a real difference for patients."
In the US, Xalkori is currently approved to treat patients with metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
The company said that it will work closely with the FDA to develop Xalkori for ROS1-positive NSCLC as well as provide the information needed to support a potential regulatory submission.